Amrutanjan Health Care Q2 FY27 Results & Earnings Intelligence
AMRUTANJANStructural risk assessment following Q2-FY27 | 30 Sep 26 earnings.
₹135.2 Cr
Reported
₹23.1 Cr
+20.2% YoY•+185.2% QoQ
₹17.3 Cr
+23.8% YoY•+295.8% QoQ
35/ 100
+15 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q2-FY27 | 30 Sep 26 | Q2-FY26 | 30 Sep 25 | YoY Δ | Q1-FY27 | 30 Jun 26 | QoQ Δ |
|---|---|---|---|---|---|
| Revenue from Operations | ₹135.2 Cr | N/A | N/A | N/A | N/A |
| Revenue (Total Income) | ₹138.2 Cr | ₹122.0 Cr | +13.3% | ₹106.8 Cr | +29.4% |
| Operating Profit (EBITDA) | ₹23.1 Cr | ₹19.2 Cr | +20.2% | ₹8.1 Cr | +185.2% |
| Profit Before Tax (PBT) | ₹23.1 Cr | ₹19.2 Cr | +20.2% | ₹6.1 Cr | +280.5% |
| EBIT Margin | 16.71% | 15.75% | +96 bps | 7.58% | +913 bps |
| Net Profit (PAT) | ₹17.3 Cr | ₹14.0 Cr | +23.8% | ₹4.4 Cr | +295.8% |
| Interest Expense | ₹0.0 Cr | ₹0.0 Cr | -10.1% | ₹0.0 Cr | +1.8% |
| Operating Cash Flow | ₹-2.1 Cr | ₹10.9 Cr | -119.6% | N/A | N/A |
| Basic EPS (₹/share) | ₹5.98 | N/A | N/A | N/A | N/A |
Sources:Official BSE/NSE Disclosures & Financial Filings
Core operating EBITDA margin of 16.7% reflects operating leverage, gross spread absorption, and input cost discipline against revenue.
Sentinel Executive Summary
Core Earnings Synthesis"Amrutanjan Health Care Limited currently sits within Flagium's Watch category. However, recent periods have introduced early signs of competitive and operating pressure. Despite positive top and bottom-line growth, triggers like 'Universal Inventory Divergence', 'Inventory Stress' indicate underlying structural risk. While not currently existential, persistent friction suggests that structural risk is rising."
Amrutanjan Health Care Limited posted steady top-line growth and bottom-line stability, demonstrating resilient execution in its core markets. While the underlying business remains fundamentally sound, the presence of 4 active risk warnings highlights minor operational or working capital inefficiencies to keep on the watch list.
🟢 Key Operational & Structural Positives
- ✓Revenue Growth: Quarterly revenue moved +13.3% YoY and +29.4% QoQ, reflecting demand and volume trends.
- ✓Net Profit Expansion: Profit after tax moved +23.8% YoY and +295.8% QoQ, settling at ₹17.3 Cr.
- ✓Operating Margins: Operating margin moved +96 bps YoY and +913 bps QoQ to 16.71%.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Resolution of 'Universal Inventory Divergence': AMRUTANJAN: YoY Inventory growth (+63.6%) outpaced Revenue growth (+13.3%) by +50.3 pp (Inventory holding ratio increased +44.4%).
- ⚠Resolution of 'Inventory Stress': Inventory growth (63.6%) significantly outpaced revenue growth (13.3%).
- ⚠Resolution of 'Working Capital Expansion': Working capital expansion detected: Receivable days increased by 2.4%.
Flagium Risk Signals
Automated Forensic SignalsUniversal Inventory Divergence • Inventory Stress • Working Capital Expansion • Industrial Margin Stress
AMRUTANJAN: YoY Inventory growth (+63.6%) outpaced Revenue growth (+13.3%) by +50.3 pp (Inventory holding ratio increased +44.4%).
Inventory growth (63.6%) significantly outpaced revenue growth (13.3%).
Working capital expansion detected: Receivable days increased by 2.4%.
AMRUTANJAN: Raw material costs consumed an additional 13.2% of revenue YoY.
🎙️ Amrutanjan Health Care (AMRUTANJAN) Q2 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
No earnings call transcript was available
for this reporting period.
What to do next
Explore AMRUTANJAN's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View AMRUTANJAN profile →See how Healthcare peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q2-FY27 | 30 Sep 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
Same Company
📬 Flagium Risk Brief — Track forensic risks on AMRUTANJAN & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.